Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid H Olsen; Jens B Sørensen; Birgitte Federspiel; Andreas Kjaer; Carsten P Hansen; Ulrich Knigge; Seppo W Langer

doi:10.1100/2012/170496

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid H Olsen, Jens B Sørensen, Birgitte Federspiel, Andreas Kjaer, Carsten P Hansen, Ulrich Knigge, Seppo W Langer

69 Citationer (Scopus)

Abstract

Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

Originalsprog	Engelsk
Tidsskrift	Scientific World Journal
Vol/bind	2012
Sider (fra-til)	170496
Antal sider	4
ISSN	1537-744X
DOI	https://doi.org/10.1100/2012/170496
Status	Udgivet - 2012

Adgang til dokumentet

10.1100/2012/170496

Citationsformater

@article{411451f9de8943c48f722757e9c994a1,

title = "Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas",

abstract = "Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.",

author = "Olsen, {Ingrid H} and S{\o}rensen, {Jens B} and Birgitte Federspiel and Andreas Kjaer and Hansen, {Carsten P} and Ulrich Knigge and Langer, {Seppo W}",

year = "2012",

doi = "10.1100/2012/170496",

language = "English",

volume = "2012",

pages = "170496",

journal = "Scientific World Journal",

issn = "1537-744X",

publisher = "The/ScientificWorld Ltd",

}

TY - JOUR

T1 - Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

AU - Olsen, Ingrid H

AU - Sørensen, Jens B

AU - Federspiel, Birgitte

AU - Kjaer, Andreas

AU - Hansen, Carsten P

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2012

Y1 - 2012

N2 - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

AB - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

U2 - 10.1100/2012/170496

DO - 10.1100/2012/170496

M3 - Journal article

C2 - 22973169

SN - 1537-744X

VL - 2012

SP - 170496

JO - Scientific World Journal

JF - Scientific World Journal

ER -

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater